Skip to main content

Cepheid Reports 45-Percent Increase in Q3 Revenues

NEW YORK, Nov. 4 (GenomeWeb News) - Cepheid yesterday reported a 45-percent increase in revenue for the third quarter of 2005.

 

Revenues for the quarter ended Sept. 30 totaled $20.4 million, compared to $14.1 million during the same quarter last year. The company attributed the increase primarily to a growth in product sales, including sales of reagents and disposables.

 

R&D spending during the quarter increased slightly to $4.8 million, compared to $4 million during the third quarter last year.

 

Cepheid reported a net loss of $3.3 million during the third quarter, compared with a net loss of $2.9 million during the same quarter last year.

 

As of Sept. 30, Cepheid had $10 million in cash and cash equivalents, and $30.2 million in marketable securities.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.